Mersana Therapeutics (MRSN) Misses Q1 EPS by 9c

Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.52), $0.09 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Sanuwave Q2 2026 revenue tops revised guidance range
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings